Atriva Therapeutics to take part in three major conferences in San Francisco, USA, in the upcoming week
Atriva Therapeutics takes part in four conferences in the upcoming months
Tübingen (Germany), September 4, 2019 – Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced its participation in four upcoming partnering conferences worldwide.
Atriva Therapeutics is one of four companies to receive the Biomarker Validation Award and aims to validate a biomarker for monitoring of MEK inhibition by the clinical-stage influenza therapy ATR-002. The award will be in the form of lab services with the Integrated Biobank of Luxembourg.
More Articles ...
- Atriva Therapeutics Starts Clinical Development of novel Host-Targeting Antiviral ATR-002 Against Influenza
- Wirtschaftswoche: 1,25 Mio. Euro für den Kampf gegen Viren
- Atriva Therapeutics announces first closing of series A financing round
- Atriva adds Dr. Christian Wallasch to its executive management team.